Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 9/20 | 0.37 |
| ▸ | ERBB2 | P04626 | 5/20 | 0.37 |
| ▸ | CCNK | O75909 | 7/20 | 0.35 |
| ▸ | CDK12 | Q9NYV4 | 7/20 | 0.35 |
| ▸ | CCNA2 | P20248 | 4/20 | 0.35 |
| ▸ | CDK2 | P24941 | 4/20 | 0.35 |
| ▸ | CDK7 | P50613 | 4/20 | 0.35 |
| ▸ | CCNH | P51946 | 4/20 | 0.35 |
| ▸ | MNAT1 | P51948 | 4/20 | 0.35 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.34 |
| ▸ | BTK | Q06187 | 2/20 | 0.33 |
| ▸ | CDK14 | O94921 | 1/20 | 0.32 |
| ▸ | CCNY | Q8ND76 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30377666 | 1.00 | EGFR (0.37) | EGFRERBB2CCNKCDK12CCNA2 | |
| SCHEMBL25253982 | 0.94 | EGFR (0.38) | EGFRERBB2CCNKCDK12CCNA2 | |
| SCHEMBL30377663 | 0.94 | EGFR (0.38) | EGFRERBB2CCNKCDK12CCNA2 | |
| SCHEMBL30378144 | 0.93 | EGFR (0.37) | EGFRERBB2CCNKCDK12CCNA2 | |
| SCHEMBL25214030 | 0.93 | EGFR (0.37) | EGFRERBB2CCNKCDK12CCNA2 | |
| SCHEMBL25210761 | 0.90 | CCNK (0.36) | EGFRERBB2CCNKCDK12CCNA2 | |
| SCHEMBL30377667 | 0.90 | CCNK (0.36) | EGFRERBB2CCNKCDK12CCNA2 | |
| SCHEMBL25220667 | 0.89 | EGFR (0.35) | EGFRBTK | |
| SCHEMBL30378151 | 0.89 | EGFR (0.35) | EGFRBTK | |
| SCHEMBL25211732 | 0.86 | JAK2 (0.38) | EGFRERBB2CCNKCDK12CCNA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240425453-A1 | ISOINDOLINES AS PMS2 INHIBITORS | CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED (GB) | 2024-12-26 | — | — | US | claimed |
| CN-118317949-A | Isoindolines as PMS2 inhibitors | 奈奥芬莱有限公司 | 2024-07-09 | — | — | CN | claimed |
| WO-2023094834-A1 | ISOINDOLINES AS PMS2 INHIBITORS | Neophore Limited (GB) | 2023-06-01 | — | — | WO | claimed |
| US-20240425453-A1 | ISOINDOLINES AS PMS2 INHIBITORS | CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED (GB) | 2024-12-26 | — | — | US | disclosed |
| CN-118317949-A | Isoindolines as PMS2 inhibitors | 奈奥芬莱有限公司 | 2024-07-09 | — | — | CN | disclosed |
| WO-2023094834-A1 | ISOINDOLINES AS PMS2 INHIBITORS | Neophore Limited (GB) | 2023-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240425453-A1 | ISOINDOLINES AS PMS2 INHIBITORS | PMS2, MSH2, RECQL | EGFR 3420/4885ERBB2 1439/4885CCNK 121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.